{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:03:40Z","timestamp":1787501020212,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.drudis.2025.104469","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T14:04:42Z","timestamp":1757772282000},"page":"104469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Status and CNS Adverse Drug Report of Sphingosine-1-Phosphate receptor modulators in multiple sclerosis"],"prefix":"10.1016","volume":"30","author":[{"given":"Ritika","family":"Haldar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8927-9970","authenticated-orcid":false,"given":"Abhijit","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104469_b0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1083\/jcb.114.1.155","article-title":"Sphingosine-1-phosphate a novel lipid involved in cellular proliferation","volume":"114","author":"Zhang","year":"1991","journal-title":"J Cell Biol"},{"key":"10.1016\/j.drudis.2025.104469_b0010","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/jcb.20097","article-title":"Generation and metabolism of bioactive sphingosine-1-phosphate","volume":"92","author":"Stunff","year":"2004","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.drudis.2025.104469_b0015","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.4049\/jimmunol.164.11.5761","article-title":"FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction expansion and memory","volume":"164","author":"Pinschewer","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2025.104469_b0020","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1084\/jem.20041509","article-title":"Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit","volume":"201","author":"Lo","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2025.104469_b0025","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2025.104469_b0030","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1146\/annurev-biochem-062411-130916","article-title":"Sphingosine-1-phosphate and its receptors structure signaling and influence","volume":"82","author":"Rosen","year":"2013","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.drudis.2025.104469_b0035","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jcb.20127","article-title":"Structural and functional characteristics of S1P receptors","volume":"92","author":"Sanchez","year":"2004","journal-title":"J Cell Biochem"},{"issue":"28","key":"10.1016\/j.drudis.2025.104469_b0040","doi-asserted-by":"crossref","first-page":"29367","DOI":"10.1074\/jbc.M403937200","article-title":"The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis","volume":"279","author":"Kono","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2025.104469_b0045","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature02284","article-title":"Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1","volume":"427","author":"Matloubian","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104469_b0050","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.2353\/ajpath.2010.091234","article-title":"Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices","volume":"176","author":"Miron","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.drudis.2025.104469_b0055","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1007\/s00415-021-10910-1","article-title":"Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature","volume":"269","author":"Sriwastava","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.drudis.2025.104469_b0060","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2025.104469_b0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jns.2013.02.011","article-title":"Fingolimod direct CNS effects of S1P receptor modulation and implications in multiple sclerosis therapy","volume":"328","author":"Groves","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.drudis.2025.104469_b0070","first-page":"385","article-title":"Sphingosine 1-phosphate receptor modulators for multiple sclerosis CNS","volume":"35","author":"Roy","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2025.104469_b0075","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrm1103","article-title":"Sphingosine-1-phosphate an enigmatic signalling lipid","volume":"4","author":"Spiegel","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.drudis.2025.104469_b0080","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/ni1545","article-title":"Finding a way out: lymphocyte egress from lymphoid organs","volume":"8","author":"Schwab","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.drudis.2025.104469_b0085","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.celrep.2012.09.021","article-title":"The transporter Spns2 is required for secretion of lymph but not plasma sphingosine-1-phosphate","volume":"2","author":"Mendoza","year":"2012","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2025.104469_b0090","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-2202-12-40","article-title":"The role of shear stress in blood-brain barrier endothelial physiology","volume":"12","author":"Cucullo","year":"2011","journal-title":"BMC Neurosci"},{"key":"10.1016\/j.drudis.2025.104469_b0095","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/glia.21021","article-title":"Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions","volume":"58","author":"Van Doorn","year":"2010","journal-title":"Glia"},{"key":"10.1016\/j.drudis.2025.104469_b0100","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1096\/fj.10-173203","article-title":"Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model","volume":"25","author":"Kim","year":"2011","journal-title":"FASEB J"},{"key":"10.1016\/j.drudis.2025.104469_b0105","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.addr.2019.12.003","article-title":"Sphingolipids in Alzheimer's disease, how can we target them?","volume":"159","author":"Crivelli","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.drudis.2025.104469_b0110","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ana.22426","article-title":"Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis","volume":"69","author":"Cohen","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.drudis.2025.104469_b0115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12883-017-0794-5","article-title":"Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study","volume":"17","author":"Saida","year":"2017","journal-title":"BMC Neurol"},{"key":"10.1016\/j.drudis.2025.104469_b0120","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald criteria\u201d","volume":"58","author":"Polman","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.drudis.2025.104469_b0125","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A Placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104469_b0130","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/jpet.107.127183","article-title":"Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis","volume":"323","author":"Foster","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2025.104469_b0135","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2025.104469_b0140","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.wnl.0000327609.57688.ea","article-title":"FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis","volume":"71","author":"Mehling","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2025.104469_b0145","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1126\/science.1070238","article-title":"Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists","volume":"296","author":"Mandala","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.drudis.2025.104469_b0150","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa052643","article-title":"Oral fingolimod (FTY720) for relapsing multiple sclerosis","volume":"355","author":"Kappos","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104469_b0155","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1517\/14740338.2014.920820","article-title":"Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis","volume":"13","author":"Ward","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.drudis.2025.104469_b0160","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1742-1241.2011.02721.x","article-title":"Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis","volume":"65","author":"Singer","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.drudis.2025.104469_b0165","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104469_b0170","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(02)08430-1","article-title":"Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN)","volume":"359","author":"Durelli","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104469_b0175","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1212\/01.WNL.0000034080.43681.DA","article-title":"Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial","volume":"59","author":"Panitch","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2025.104469_b0180","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1212\/01.WNL.0000032256.35561.D6","article-title":"A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS","volume":"59","author":"Clanet","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2025.104469_b0185","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/jamaneurol.2016.1451","article-title":"Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study","volume":"73","author":"Kappos","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.drudis.2025.104469_b0190","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S1474-4422(13)70102-9","article-title":"Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study","volume":"12","author":"Selmaj","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2025.104469_b0195","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1600-6143.2005.00754.x","article-title":"The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I","volume":"5","author":"Koyrakh","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.drudis.2025.104469_b0200","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104469_b0205","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1212\/01.WNL.0000146958.77317.3E","article-title":"Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study","volume":"63","author":"Panitch","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2025.104469_b0210","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(98)10039-9","article-title":"Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS","volume":"352","author":"Kappos","year":"1998","journal-title":"Lancet"},{"issue":"18_Suppl","key":"10.1016\/j.drudis.2025.104469_b0215","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1212\/WNL.98.18_supplement.3510","article-title":"Safety and tolerability of conversion to siponimod in patients with advancing relapsing multiple sclerosis: a subgroup analysis by race and ethnicity of EXCHANGE interim data (P8-4.006)","volume":"98","author":"Bar-Or","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2025.104469_b0220","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.drudis.2025.104469_b0225","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2025.104469_b0230","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1474-4422(16)00018-1","article-title":"Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Cohen","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2025.104469_b0235","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1136\/jnnp-2013-307282","article-title":"Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial","volume":"85","author":"Olsson","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.drudis.2025.104469_b0240","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","article-title":"Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment","volume":"73","author":"Hatcher","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.drudis.2025.104469_b0245","doi-asserted-by":"crossref","first-page":"e762","DOI":"10.1212\/WNL.0000000000200606","article-title":"Long-term treatment with ponesimod in relapsing-remitting multiple sclerosis: results from randomized phase 2b core and extension studies","volume":"99","author":"Freedman","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2025.104469_b0250","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(08)61619-0","article-title":"Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double blind, placebo-controlled phase IIb study","volume":"372","author":"Kappos","year":"2008","journal-title":"Lancet"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625001825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625001825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T21:29:57Z","timestamp":1764278997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625001825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1359644625001825"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104469","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Status and CNS Adverse Drug Report of Sphingosine-1-Phosphate receptor modulators in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104469","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104469"}}